PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet | 1 | of | 1

Complete if Known	
Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE
Art Unit	1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2020.01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number – Number – Kind Code[2] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RD	1	US-4,053,638	10-11-77	Litchfield et al.	
RD	2	US-4,083,974	04-11-87	Turi	
RD	3	US-4,339,440	07-13-82	Bajusz et al.	
RD	4	US-5,918,568	07-06-99	Gjerløv	
RD	5	US-6,110,908	08-29-00	Guthery	
RD	6	US-6,143,790	11/07/00	Hallinan et al.	
RD	7	US-6,448,058 B1	09-10-02	Patel et al.	
RD	8	US-6,613,879 B1	09-02-03	Firestone et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document – Country Code[3] – Number[4] – Kind Code[5] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
RD	9	WO 02/089739 A2	11-14-02	NewBiotics, Inc.		
RD	10	WO 03/088913 A2	10-30-03	NewBiotics, Inc.		

Examiner's Signature	Desai	Date Considered	5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE
Art Unit	1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2020.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	1	de GROOT, F.M.H. et al. "Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin" *J. Med. Chem.* (1999) 42(25):5277-5283	
	2	MEINNEL, T. "Vers une conception rationnelle de nouveaux agents antibactériens" *Pathol. Biol.* (Oct. 1999) 47(8):780-783	X
RD	3	International Preliminary Examination Report dated December 15, 2004 for PCT/US2002/036124	

Examiner's Signature	RDesai	Date Considered	5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE et al.
Art Unit	1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2020.01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number – Kind Code[2] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RD	1	US-6,159,706	12-12-2000	Shepard	
D	2	US-6,245,750	06-12-2001	Shepard	
R	3	US-6,339,151	01-15-2002	Shepard et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] – Number[4] – Kind Code[5] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
RD	4	WO 99/08110	02-18-1999	NewBiotics, Inc.		
RD	5	WO 99/37753	07-29-1999	NewBiotics, Inc.		
RD	6	WO 01/07454 A1	02-01-2001	NewBiotics, Inc.		
RD	7	WO 98/13059 A	04-02-1998	Squibb Bristol Myers		

Examiner's Signature	RDesai	Date Considered	5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE, et al.
Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	NB 2020.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	1	APFEL, C. et al. "Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents" (2000) *J. Med. Chem.* 43:2324-2331	
	2	APFEL, C.M. et al. "Peptide deformylase as an antibacterial drug target: Assays for detection of its inhibition in *escherichia coli* cell homogenates and intact cells" (April, 2001a) *Anti. Agents and Chemo.* 45(4):1053-1057	
	3	APFEL, C.M. et al. "Peptide deformylase as an antibacterial drug target: Target validation and resistance development" (April, 2001b) *Anti. Agents and Chemo.* 45(4):1058-1064	
	4	BECKER, A. et al. "Iron center, substrate recognition and mechanism of peptide deformylase" (1998) *Nat. Struct. Biol.* 5(12):1053-1058	
	5	CHAN, Michael K. et al. "Crystal structure of the *escherichia coli* peptide deformylase" *Biochem.* (1997) 36:13904-13909	
	6	CHEN, D.Z. et al. "Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor" (2000) *Biochem.* 39(6):1256-1262	
	7	CLEMENTS, J.M. et al. "Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor" (February, 2001) *Anti. Agents and Chemo.* 45(2):563-570	
	8	de GROOT, F.M.H. et al. "Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin" (2000) *J. Med. Chem.* 43:3093-3102	
	9	DUBOWCHICK, G.M. et al. (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin, *Bioorg & Medicinal Chem. Letters* 8(23):3341-3346.	
	10	DURAND, D.J. et al. "Peptide deformylase inhibitors of bacterial peptide deformylases" (July 15, 1999) *Arch. Biochem. And Biophysics.* 367(2): 297-302	
	11	GIGLIONE, C. et al. "Peptide deformylase as a target for new generation, broad spectrum antimodrobial agents" (2000a) *Mol. Microbiol.* 36(6):1197-1205	
	12	GIGLIONE, C. et al. "Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms" *EMBO J.* (2000b) 19(21):5916-5929	
	13	HAO, B. et al. "Structural basis for the design of antibiotics targeting peptide deformylase" (1999) *Biochem.* 38(15):4712-4719	
	14	HU, Y.J. et al. "H-phosphonate derivatives as novel peptide deformylase inhibitors" (1998) *Bioorg Med Chem Letts.* 8(18):2479-2482	
	15	HUNTINGTON, K.M. et al. "Synthesis and antibacterial activity of peptide deformylase inhibitors" (2000) *Biochem.* 39(15):4543-4551	
	16	JAYASEKERA, M.M.K. et al. "Novel nonpeptidic inhibitors of peptide deformylase" (Sept. 15, 2000) *Arch. Biochem. & Biophys.* 381(2):313-316	
	17	LACKEY, D.B. et al. (2001) Enzyme - catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB 1011 by thymidylate synthase, *Biochem. Pharmocology* 61:179-189	
	18	MEINNEL, T. "Vers une conception rationnelle de nouveaux agents antibactériens" (1999) *Pathol. Biol.* 47(8):780-783	

Examiner's Signature	R Deras	Date Considered	5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE, et al.
Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	NB 2020.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	19	MEINNEL, T. et al. "Methionine as translation start signal: A review of the enzymes of the pathway in *Escherichia coli*" (1993) *Biochimie.* 75(12):1061-1075	
	20	RAGUSA S., et al. "Control of Peptide deformylase activity by metal cations" (1998) *J.Mol.Biol.*, 280:551-523	
	21	RAJAGOPALAN, P.T.R. et al. "Purification, characterization, and inhibition of peptide deformylase from *Escherichia coli*" (1997) *Biochem.* 36(45):13910-13918	
	22	RAJAGOPALAN, P.T.R. et al. "Oxygen-mediated inactivation of peptide deformylase" (August 28, 1998) *J. Biol Chem.* 273(35):22305-22310	
	23	WEI Y. et al. "Continuous spectrophotometric assay of peptide deformylase" (1997) *Anal Biochem.* 250(1):29-34	
	24	WEI, Y. et al. "Identification of a potent peptide deformylase inhibitor from a rationally designed combinatorial library" (2000a) *J Comb Chem.* 2(6):650-657	
	25	WEI, Y. et al. "Activiation of antibacterial prodrugs by peptide deformylase" (2000b) *Bioorg Med Chem Letts.* 10(10):1073-1076	
RS	26	BODUSZEK BOGDAN, English Abstract "Synthesis of novel Phosphonopeptides derived from pyridylmethylphosphonate diphenyl esters	
RS	27	LIU, et al. English Abstract "Synthesis and anticancer activities of new 5-fluorouracil-1-yl phosphonotripeptides"	
RS	28	Copy of Written Opinion for PCT/US02/14500	
RS	29	Copy of International Search Report for PCT/US02/36124	
RS	30	Copy of European Supplemental Search Report for EP Appl. No. 02741696.5	

Examiner's Signature	Roesan	Date Considered	5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.